ClinicalTrials.gg
RecruitingNCT07479433NAVIGATE-PCIUpdated Nov 12, 2026

The NAVIGATE-PCI Registry: A New Approach to VIew CT-derived Guidance Ahead of Stenting To Plan Efficient PCI

An observational study in Coronary Artery Disease (CAD), sponsored by HeartFlow, Inc.. Recruiting at 22 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by HeartFlow, Inc. · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 12, 2026Primary completion moved21 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
5,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Coronary Artery Disease by HeartFlow, Inc. — 4 open to participants now, 5 under way, none of them phase 3. Coronary Artery Disease · HeartFlow, Inc..

Started
2026
with 2 others
Observational
7 of 12
2 open now
Registered
10th of 12
by date

Among the 12 studies in Coronary Artery Disease by HeartFlow, Inc., this one is one of 3 that started in 2026, is one of 7 observational ones, and was the 10th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

4 of the 12 studies in Coronary Artery Disease by HeartFlow, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Coronary Artery Disease by HeartFlow, Inc., or all of them as a file.
02

Study summary

The objective of Heartflow's NAVIGATE-PCI Registry is to collect observational data about the management of patients before and after deployment of Heartflow's PCI Navigator.

Read the detailed description

Heartflow's NAVIGATE-PCI Registry is a post-market, multi-center, data collection registry assessing confidence in procedure planning, time of procedure, contrast usage during procedure, radiation usage during procedure, invasive imaging (angiographic or other), and resource utilization. Sites will provide retrospective data from patients receiving an elective PCI prior to the deployment of PCI Navigator vs. after deployment and operator training on how to use the information provided by PCI Navigator. Baseline demographic, medical history, procedural, and in-hospital outcome information will be collected following the procedure. No post discharge follow-up data will be collected.

03

Conditions studied

  • Coronary Artery Disease (CAD)

Keywords

  • CAD
  • PCI Navigator
  • CT-Guided PCI
  • PCI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Deidentified data will be collected for all patients included in the registry who had a CCTA with acceptable image quality prior to elective PCI and are included by the site in the registry. Patients with prior CABG or patients with intervention planned in a previously stented vessel territory are excluded.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. CCTA completed ≤90 days prior to elective PCI with acceptable image quality according to Heartflow's image quality requirements
  2. Referred for elective PCI
  3. Clinically stable without symptoms suggestive of acute coronary syndrome (ACS) at the time of the intervention

Exclusion criteria

Exclusion Criteria (all must be present):

  1. ED presentation (at the time of the referral for PCI)
  2. Previous coronary artery bypass graft (CABG)
  3. Planned intervention in a previously stented vessel territory
  4. Acute chest pain (in patients who have not been ruled out for ACS)
  5. Participating in a conflicting study being undertaken during the PCI
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
5,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Group 1: No PCI Navigator

    This group includes consecutive patients who have undergone a CCTA a maximum of 90 days prior to an elective PCI at the study site; the CCTA is not required to have been used in procedural planning but must have acceptable image quality according to Heartflow's image quality requirements

  • Group 2: Intraprocedural PCI Planning

    This group includes patients who had a CCTA and a referral for elective PCI following the introduction of the PCI Navigator at the study site. The PCI should be performed no more than 90 days following the CCTA. Interventionalists will document their procedural plan after initial invasive angiographic images are reviewed but before reviewing the information provided by the PCI Navigator, and then again after reviewing the information provided by the PCI Navigator. Usage of invasive imaging following review of the PCI Navigator is at the discretion of the interventionalist.

    Diagnostic Test: Heartflow PCI Navigator

  • Group 3: Preprocedural Planning

    This group includes patients who had a CCTA and a referral for elective PCI following the introduction of the PCI Navigator at the study site. The PCI should be performed no more than 90 days following the CCTA. Interventionalists will document their procedural plan before reviewing the information provided by the PCI Navigator and prior to initial invasive angiographic imaging, and then again after reviewing the information provided by the PCI Navigator. Usage of angiographic and other invasive imaging following review of the PCI Navigator is at the discretion of the interventionalist.

    Diagnostic Test: Heartflow PCI Navigator

Interventions

  • Diagnostic testHeartflow PCI Navigator

    Heartflow PCI Navigator is the only integrated, AI-driven PCI planning tool that gives interventional cardiologists a patient-specific 3D model, detailing anatomy, plaque composition, and lesion-specific physiology, all aligned to optimize potential stent placement. PCI Navigator delivers a streamlined view of essential information for cath lab decision-making by integrating all relevant measurements, including IVUS-like and FFR-like pullback visualizations, into one seamless experience, which typically requires significant time and effort to obtain in the cath lab.

06

What researchers measure

Primary outcomes

  1. Primary Endpoint

    The primary endpoint will be assessed only in Group 2 and is a change in procedural plan following review of the information provided by PCI Navigator compared to procedural plan with angiographic imaging alone. The primary endpoint will be measured by calculating the percentage of patients in whom a change of plan was documented following review of the PCI Navigator tool compared to the plan documented prior to using the tool.

    Time frame: 90 Days

Secondary outcomes

  1. Changes in confidence with and without PCI Navigator (assessed in Groups 2 and 3 as two separate analyses)

    Time frame: 90 days for Group 2, 18 months for Group 3

  2. Change in procedural time with and without PCI Navigator

    Time frame: 90 days

  3. Change in contrast usage with and without PCI Navigator

    Time frame: 90 days

  4. Change in radiation usage during PCI with and without PCI Navigator

    Time frame: 90 days

  5. Change in invasive imaging (angiographic or other) with and without PCI Navigator

    Time frame: 90 days

  6. Change in resource utilization with and without PCI Navigator

    Time frame: 90 days

Other outcomes

  1. Exploratory and Safety Endpoint

    Perform all endpoint analyses with a comparison of male vs. female as an added variable

    Time frame: 5 years

  2. Exploratory and Safety Endpoint

    Procedural complications and in-hospital outcomes

    Time frame: 5 years

07

Study locations

22 of 22 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2026 to primary completion in Aug 2026, 5 months.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Aug 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2026
First posted
Mar 18, 2026
StartActual
Mar 11, 2026
Primary completionActual
Aug 23, 2026was Sep 2026
CompletionEst.
Dec 31, 2032
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
21 sites added
Show 21 added (21 United States)
  • Stanford Medical Center · Palo Alto, United States
  • University of Miami · Miami, United States
  • Naples Comprehensive Health · Naples, United States
  • University of South Florida · Tampa, United States
  • Northwestern Memorial Hospital · Chicago, United States
  • Advocate Illinois Masonic Medical Center · Chicago, United States
  • Endeavor Health · Glenview, United States
  • Carle Foundation Hospital · Urbana, United States
  • Norton Hospital · Louisville, United States
  • Corewell Health William Beaumont University Hospital · Royal Oak, United States
  • Allina Health Minneapolis Heart Institute · Minneapolis, United States
  • CentraCare - St. Cloud Hospital · Saint Cloud, United States
  • Virtua Our Lady of Lourdes Hospital · Camden, United States
  • St. Francis Hospital and Heart Center · Roslyn, United States
  • Cone Health Moses Cone Hospital · Greensboro, United States
  • Oregon Health & Science University · Portland, United States
  • Allegheny General Hospital · Pittsburgh, United States
  • Lankenau Medical Center · Wynnewood, United States
  • WellSpan York Hospital · York, United States
  • Prisma Health Richland Hospital · Columbia, United States
  • UVA Health University Medical Center · Charlottesville, United States
Nov 12, 2026
Primary completion
Sep 30, 2026→Aug 23, 2026 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    21 sites added
    Show 21 added (21 United States)
    • Stanford Medical Center · Palo Alto, United States
    • University of Miami · Miami, United States
    • Naples Comprehensive Health · Naples, United States
    • University of South Florida · Tampa, United States
    • Northwestern Memorial Hospital · Chicago, United States
    • Advocate Illinois Masonic Medical Center · Chicago, United States
    • Endeavor Health · Glenview, United States
    • Carle Foundation Hospital · Urbana, United States
    • Norton Hospital · Louisville, United States
    • Corewell Health William Beaumont University Hospital · Royal Oak, United States
    • Allina Health Minneapolis Heart Institute · Minneapolis, United States
    • CentraCare - St. Cloud Hospital · Saint Cloud, United States
    • Virtua Our Lady of Lourdes Hospital · Camden, United States
    • St. Francis Hospital and Heart Center · Roslyn, United States
    • Cone Health Moses Cone Hospital · Greensboro, United States
    • Oregon Health & Science University · Portland, United States
    • Allegheny General Hospital · Pittsburgh, United States
    • Lankenau Medical Center · Wynnewood, United States
    • WellSpan York Hospital · York, United States
    • Prisma Health Richland Hospital · Columbia, United States
    • UVA Health University Medical Center · Charlottesville, United States
    Primary completion Sep 30, 2026→Aug 23, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07479433
Lead sponsor
HeartFlow, Inc.
Responsible party
Sponsor
First posted
Mar 18, 2026
Start date
Mar 11, 2026
Primary completion
Aug 23, 2026
Completion
Dec 31, 2032 (estimated)
Last update
Nov 12, 2026

Study contacts

Abby Doctolero
Contact
adoctolero@heartflow.com
650-241-1221
Sarah Mullen
Contact
smullen@heartflow.com
650-241-1221
Ziad Ali, MD, DPhil
principal investigator · St. Francis Hospital & Heart Center Columbia University
Todd C. Villines, MD
principal investigator · University of Virginia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion